Laparoscopic and Percutaneous Ultrasound Guided Radiofrequency Ablation for Hepatocellular Carcinoma: a Preliminary Study.
- Author:
Min Kyu JUNG
1
;
Jong Hyup LEE
;
Tae Seok KIM
;
Hyun Soo KIM
;
Chang Min CHO
;
Won Young TAK
;
Young Oh KWEON
;
Sung Kook KIM
;
Yong Hwan CHOI
;
Joon Mo CHUNG
Author Information
1. Department of Internal Medicine, Liver Research Institute, Kyungpook National University College of Medicine, Daegu, Korea. wytak@knu.ac.kr
- Publication Type:Original Article ; English Abstract
- Keywords:
Radiofrequency ablation;
Hepatocellular carcinoma
- MeSH:
Adult;
Aged;
Carcinoma, Hepatocellular/radiography/*surgery/ultrasonography;
*Catheter Ablation/adverse effects;
English Abstract;
Female;
Human;
*Laparoscopy;
Liver Neoplasms/radiography/*surgery/ultrasonography;
Male;
Middle Aged;
Neoplasm Recurrence, Local;
Tomography, X-Ray Computed;
*Ultrasonography, Interventional
- From:The Korean Journal of Hepatology
2002;8(2):209-217
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Radiofrequency ablation (RFA) is emerging as a new therapeutic method in the management of hepatocellular carcinoma (HCC). We report the results of 64 patients with a follow-up interval of 3 to 19 months. METHOD: Sixty-four patients with 82 nodules underwent ultrasound guided RFA. The mean tumor diameter was 2.5+/-1.0 cm. Laparoscopic ultrasound guided RFA was performed in 38 cases, and percutaneous ultrasound guided RFA in 26 cases. The therapeutic efficacy was evaluated by means of three-phase dynamic abdominal computed tomography (CT) performed within at least one week after ablating. The recurrence was evaluated after treatment by means of abdominal CT and alpha fetoprotein every 3 months. We calculated cumulative recurrence rates, survival rates of patients, and found out complication of RFA. RESULTS: Cumulative recurrence rates in 3, 6, 12 months after RFA was 8.8%, 15.8%, 25.9%. 12 cases were recurred during follow-up. Among them, intrahepatic recurrences were noted in 11 cases, local recurrences in 3 cases. Cumulative survival curves indicated that survival rate was 95% at the third month, 94% at the sixth month, 81% at the twelfth month. After RFA, the alpha fetoprotein level was decreased significantly after 1 month (p<0.05), and serum transaminase levels were transiently elevated (p<0.01) but returned to normal within one week. Complications of RFA were not serious, and resolved spontaneously. CONCLUSION: RFA can be considered a useful new treatment for HCC. Laparoscopic RFA is a useful procedure for the treatment of HCC regardless of its location.
